Reduced MYC was also reported following Hsp90 inhibition of neuroblastoma and prostate cancer cells, with suppression of the malignant phenotype and augmentation of chemotherapy response, respectively [52, 53]. This evidence concerns the gene MYC and prostate carcinoma.